Kevin Roland

Kevin Roland is the Vice-President of CMC Radiopharmaceutical Development at Abdera Therapeutics, a biopharmaceutical company pioneering precision radiotherapeutics for cancer treatment. In his role, Kevin oversees the chemistry, manufacturing, and controls (CMC) aspects of Abdera’s innovative ROVEr™ platform, which integrates advanced antibody engineering to create targeted radiopharmaceuticals with tunable pharmacokinetic properties. Kevin will be speaking on “Understanding Regulations for Radiopharmaceutical Manufacturing & Supply,” sharing his expertise on navigating the complex regulatory landscape to ensure the safe and effective production of radiopharmaceuticals.